You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023138019
Dec 202360013
Jan 20247304
Feb 20243607
Mar 20243804
Apr 20242005
May 20241805
Jun 2024801
Jul 20241005
Aug 202442013
Sep 20242203
Oct 20242409
Nov 20242007
Dec 20241204
Jan 202517010
Feb 20251209
Mar 20250016
Apr 20250014
May 20250015
Jun 2025005
Total5500168